ClinicalTrials.gg
RecruitingNCT05565976DECISTUpdated Oct 4, 2022

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

A Phase 2/3 interventional study of Dapagliflozin 10mg Tab and Statins (Cardiovascular Agents) in Stroke, Ischemic, Mild Cognitive Impairment and Dementia, Vascular, sponsored by Jaime Daniel Mondragon. Recruiting at 1 site in Mexico. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Jaime Daniel Mondragon · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 1 month after the study started (first participant enrolled Aug 2020, registered Sep 2022).
  • Started Aug 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Ischemic Stroke with a site in Mexico — 9 open to participants now, 10 under way, 3 of them phase 3. Ischemic Stroke · Mexico.

Planned enrollment
6th of 13
270 · median 270
Started
2020
the only one that year
Phase 2/3
Only one
of the 19
Registered
12th of 19
by date

Among the 19 studies in Ischemic Stroke with a site in Mexico, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 2/3, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 19 studies in Ischemic Stroke with a site in Mexico are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Ischemic Stroke with a site in Mexico, or all of them as a file.
02

Study summary

Background: Dementia is an international public health problem, affecting approximately 50,000,000 people worldwide in 2018 and will triple by 2050; furthermore, reaching an approximate cost of 4 billion dollars. Given its high worldwide prevalence and probable underdiagnosis, the international guidelines for the assessment of dementia syndromes recommend the assessment of cognitive impairment in patients over 55 years of age as part of clinical practice in patients who presented an ischemic cerebrovascular event. Several risk factors associated with cognitive impairment in cerebrovascular disease are identified in the literature: 1) demographic factors (e.g., age over 65 years and female sex); 2) risk factors present prior to the ischemic stroke (e.g., cognitive impairment, physical impairment); 3) factors utilized to assess the severity of an ischemic stroke (e.g., supratentorial location, ischemic stroke in the dominant hemisphere, recurrence of ischemic strokes); 4) post-ischemic stroke factors (e.g., delirium and seizures); and 5) factors associated with neuroimaging findings (e.g., cerebral small vessel disease, cortical atrophy, and medial temporal lobe atrophy).

This is a randomized controlled trial in individuals with an acute ischemic stroke without dementia that will be treated with 10mg dapagliflozin PO q24h for 12 months and standard treatment against only standard treatment (i.e., statins, platelet antiaggregant, and hypoglycemic medications) when appropriate. The outcome measure evaluated will be global cognitive function. Cardiovascular risk factors will be associated with cognitive decline.

Read the detailed description

Detailed Description: This is a double-blind, randomized, placebo-controlled, parallel-group, 12-month longitudinal study performed at a single center (Hospital General de Zona con Medicina Familiar IMSS No. 21, León Guanajuato, México) designed to investigate the effect of dapagliflozin in participants with a recent acute stroke but no history of dementia (CDR score ≤ 0.5). A total of 270 participants are to be included (i.e., 135 on each arm).

Overall objective: To assess the effect of Dapagliflozin on cardiovascular risk (i.e., the volume of epicardial fat, volume of total carotid atherosclerotic plaque, and coronary artery calcium score) in patients with ischemic cerebrovascular disease dependent on global cognitive function at a second level teaching hospital in Mexico.

Statistical analysis: Descriptive statistics will be reported for all included variables. Statistical analysis will be performed using SPSS 25 (SPSS Inc., Chicago, IL). All variables will be examined to determine the existence of outliers and whether they meet the assumptions about a Gaussian distribution. The Shapiro-Wilk tests will be used to determine normality distribution, as well as visual inspection of histograms and Q-Q plots. Demographic and clinical variables will be summarized in proportions and percentages. The categorical variables will be evaluated to determine statistical inferences with the Mann-Whitney U test. Continuous variables will be assessed for statistical inferences using t-tests (e.g., simple, paired, one, and two samples) and Levene's test to assess equality of variances. The Kaplan-Meier method will be used to calculate the distributions of mortality and development of mild amnestic cognitive disorder and dementia syndrome. The Gehan-Breslow-Wilcoxon method will be used to assess the equality of the mortality distributions and the development of mild amnestic cognitive disorder or dementia syndrome. A multivariate analysis will be performed with a Cox regression model to assess the variables that predict mortality, and the development of a mild amnestic cognitive disorder, or dementia syndrome at 6 and 12 months in case there are differences in mortality distributions. Statistical significance will be set at p=0.05 and a Bonferroni correction will be performed for multiple comparisons.

03

Conditions studied

  • Stroke, Ischemic
  • Mild Cognitive Impairment
  • Dementia, Vascular
  • Metabolic Syndrome

Keywords

  • dapagliflozin
  • mortality
  • cognitive impairment
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages of 60 and 80 years
  • Both sexes
  • Cerebrovascular ischemic event within 15 days
  • Clinical dementia rating score ≤ 0.5
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Aphasia
  • Incomplete neuropsychological battery
  • Previously diagnosed dementia
  • Cerebrovascular ischemic stroke older than 15 days
  • History of hemorrhagic cerebrovascular event
  • Neoplasia diagnosis or evidence of a process, \< 45 mL/min at the time of inclusion
  • Liver enzyme test alterations (i.e., or alanine transaminase three times greater than normal levels, total > 2.0 mg/dL
  • Previously taking SGLT2 inhibitors
  • History of diabetic ketoacidosis
  • Recurrent urinary tract infections
  • Psychiatric disorders (e.g., dementia, psychosis, bipolar disorder, among others).
  • Less than a 12-month follow-up
  • Inability to perform chest CT (e.g., claustrophobia)
  • Incomplete medical files pertaining to the variables of interest
  • Less than 12-month follow-up
  • Decision to withdraw their participation at any moment
  • Poor adherence to medical treatment
  • Reported and documented disease complications or adverse effects (e.g., severe glycemic imbalance, diabetic ketoacidosis, or hyperosmolar hyperglycemic state, altered hepatic enzyme tests)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin

    10mg PO q24h for 12 months plus standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.

    Drug: Dapagliflozin 10mg Tab · Drug: Statins (Cardiovascular Agents) · Drug: Platelet Antiaggregant · Drug: Antidiabetic

  • Active comparator
    Standard treatment

    Standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.

    Drug: Statins (Cardiovascular Agents) · Drug: Platelet Antiaggregant · Drug: Antidiabetic

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10mg PO q24h for 12 months

    Also known as: FORXIGA

  • DrugStatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h

    Also known as: Atorvastatin, Pravastatin, Rosuvastatin

  • DrugPlatelet Antiaggregant

    Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h

    Also known as: Clopidogrel, Acetylsalicylic acid

  • DrugHypoglycemic AgentsStudies of Hypoglycemic AgentsHypoglycemic Agents pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Previously established medical treatment for type 2 diabetes will be maintained.

    Also known as: Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, α-Glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4, Cycloset, Insulin glargine, Insulin lispro, Isophane insulin

06

What researchers measure

Primary outcomes

  1. Change in Clinical Dementia Rating score as a proxy of cognitive deterioration

    Time-to-event analysis using the Kaplan-meier survival analysis via increase in Clinical Dementia Rating score greter or equal to 0.5

    Time frame: 6 and 12 months

Secondary outcomes

  1. Number of strokes after initial cerebrovascular event

    Independent stroke events

    Time frame: 12 months

Other outcomes

  1. Adverse effects due to Dapagliflozin

    Adverse effects reported due to the use of dapagliflozin

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital General de Zona IMSS 21
    León, Guanajuato 37380, Mexico
    Recruiting
08

References and documents

Publications

  • Bjergfelt SS, Sorensen IMH, Hjortkjaer HO, Landler N, Ballegaard ELF, Biering-Sorensen T, Kofoed KF, Lange T, Feldt-Rasmussen B, Sillesen H, Christoffersen C, Bro S. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification. PLoS One. 2021 Nov 23;16(11):e0260417. doi: 10.1371/journal.pone.0260417. eCollection 2021. PubMed 34813630 ↗
  • Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Erratum In: Lancet Diabetes Endocrinol. 2020 Aug;8(8):e3. doi: 10.1016/S2213-8587(20)30217-5. PubMed 32559474 ↗
  • Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23. PubMed 29573529 ↗
  • Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019 Jul;79(10):1135-1146. doi: 10.1007/s40265-019-01148-3. Erratum In: Drugs. 2019 Dec;79(18):2013. doi: 10.1007/s40265-019-01239-1. PubMed 31236801 ↗
  • Diaz-Rodriguez E, Agra RM, Fernandez AL, Adrio B, Garcia-Caballero T, Gonzalez-Juanatey JR, Eiras S. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018 Feb 1;114(2):336-346. doi: 10.1093/cvr/cvx186. PubMed 29016744 ↗
  • Esterline R, Oscarsson J, Burns J. A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease? Int Rev Neurobiol. 2020;155:113-140. doi: 10.1016/bs.irn.2020.03.018. Epub 2020 Aug 11. PubMed 32854852 ↗
  • Esterline RL, Vaag A, Oscarsson J, Vora J. MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? Eur J Endocrinol. 2018 Apr;178(4):R113-R125. doi: 10.1530/EJE-17-0832. Epub 2018 Jan 25. PubMed 29371333 ↗
  • Fani L, van Dam-Nolen DHK, Vernooij M, Kavousi M, van der Lugt A, Bos D. Circulatory markers of immunity and carotid atherosclerotic plaque. Atherosclerosis. 2021 May;325:69-74. doi: 10.1016/j.atherosclerosis.2021.03.040. Epub 2021 Apr 7. PubMed 33894597 ↗
  • Iacobellis G, Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. Obesity (Silver Spring). 2020 Jun;28(6):1068-1074. doi: 10.1002/oby.22798. Epub 2020 Apr 30. PubMed 32352644 ↗
  • Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, Dichgans M. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Jul 2;73(25):3326-3344. doi: 10.1016/j.jacc.2019.04.034. PubMed 31248555 ↗
  • Ihara M, Saito S. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs. J Alzheimers Dis. 2020;74(4):1013-1028. doi: 10.3233/JAD-200049. PubMed 32144994 ↗
  • Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018 Mar;20(3):620-628. doi: 10.1111/dom.13124. Epub 2017 Oct 26. PubMed 28950419 ↗
  • Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010 Apr;119(4):421-33. doi: 10.1007/s00401-010-0654-5. Epub 2010 Mar 4. PubMed 20204386 ↗
  • McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. PubMed 31535829 ↗
  • Mijajlovic MD, Pavlovic A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, Hermann DM, Assayag EB, Richard E, Thiel A, Kliper E, Shin YI, Kim YH, Choi S, Jung S, Lee YB, Sinanovic O, Levine DA, Schlesinger I, Mead G, Milosevic V, Leys D, Hagberg G, Ursin MH, Teuschl Y, Prokopenko S, Mozheyko E, Bezdenezhnykh A, Matz K, Aleksic V, Muresanu D, Korczyn AD, Bornstein NM. Post-stroke dementia - a comprehensive review. BMC Med. 2017 Jan 18;15(1):11. doi: 10.1186/s12916-017-0779-7. PubMed 28095900 ↗
  • Mohamed Fuad Z, Mahadzir H, Syed Zakaria SZ, Mohamed Ibrahim N. Frequency of Cognitive Impairment Among Malaysian Elderly Patients Following First Ischaemic Stroke-A Case Control Study. Front Public Health. 2020 Nov 12;8:577940. doi: 10.3389/fpubh.2020.577940. eCollection 2020. PubMed 33282811 ↗
  • Sato T, Aizawa Y, Yuasa S, Fujita S, Ikeda Y, Okabe M. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial. J Atheroscler Thromb. 2020 Dec 1;27(12):1348-1358. doi: 10.5551/jat.48009. Epub 2020 Feb 28. PubMed 32115470 ↗
  • Serena J, Irimia P, Calleja S, Blanco M, Vivancos J, Ayo-Martin O; Representacion de la Sociedad Espanola de Neurosonologia (SONES). [Ultrasound measurement of carotid stenosis: recommendations from the Spanish Society of Neurosonology]. Neurologia. 2013 Sep;28(7):435-42. doi: 10.1016/j.nrl.2012.07.011. Epub 2012 Oct 4. Spanish. PubMed 23040716 ↗
  • Suda S, Nishimura T, Ishiwata A, Muraga K, Aoki J, Kanamaru T, Suzuki K, Sakamoto Y, Katano T, Nishiyama Y, Mishina M, Kimura K. Early Cognitive Impairment after Minor Stroke: Associated Factors and Functional Outcome. J Stroke Cerebrovasc Dis. 2020 May;29(5):104749. doi: 10.1016/j.jstrokecerebrovasdis.2020.104749. Epub 2020 Mar 14. PubMed 32178931 ↗
  • Uemura MT, Maki T, Ihara M, Lee VMY, Trojanowski JQ. Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia. Front Aging Neurosci. 2020 Apr 14;12:80. doi: 10.3389/fnagi.2020.00080. eCollection 2020. PubMed 32317958 ↗
  • van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nat Rev Dis Primers. 2018 Feb 15;4:18003. doi: 10.1038/nrdp.2018.3. PubMed 29446769 ↗
  • Zlokovic BV, Gottesman RF, Bernstein KE, Seshadri S, McKee A, Snyder H, Greenberg SM, Yaffe K, Schaffer CB, Yuan C, Hughes TM, Daemen MJ, Williamson JD, Gonzalez HM, Schneider J, Wellington CL, Katusic ZS, Stoeckel L, Koenig JI, Corriveau RA, Fine L, Galis ZS, Reis J, Wright JD, Chen J. Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 2020 Dec;16(12):1714-1733. doi: 10.1002/alz.12157. Epub 2020 Oct 8. PubMed 33030307 ↗

Individual participant data

Plan to share: Yes — The study protocol, statistical analysis plan and informed consent form are available through the IMSS platform or upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Starting august 2022

Access criteria: Request IMSS institutional board

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2024, 52 months after the start.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Oct 4, 2022
StartActual
Aug 1, 2020
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jul 1, 2025
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05565976
Lead sponsor
Jaime Daniel Mondragon
Collaborators
Hospital General León, Hospital General de Zona IMSS N0. 21, University Medical Center Groningen
Responsible party
Jaime Daniel Mondragon (Principal Investigator, Clinical Professor, Universidad de Guanajuato) — Sponsor-investigator
First posted
Oct 4, 2022
Start date
Aug 1, 2020
Primary completion
Dec 31, 2024 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Oct 4, 2022

Study contacts

Omar Jiménez-Zarazúa, M.D.
Contact
drzarazuainterna@hotmail.com
+524423421626
Lourdes N Vélez-Ramírez, M.D.
Contact
nestlynoemi@gmail.com
Gabriela G López-Hernández, M.D.
study chair · Hospital General de Zona IMSS 21
Lizeth C Ramírez-Zamudio, M.D.
study chair · Hospital General de Zona IMSS 21
Jaime D Mondragón, M.D., Ph.D.
principal investigator · University Medical Center Groningen, Department of Neurology, Alzheimer Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion